On the heels of its third U.S. approval for a biosimilar, Amgen submitted an application to regulators for an oncology drug imitating Rituxan, a $5 billion drug made by Roche. The Thousand Oaks biotech giant said it submitted a biologics license application to the U.S. Food and Drug Administration for its product ABP 798 in…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
